Scottsdale, AZ (PRWEB) September 14, 2012
QualityStocks would like to highlight NeoGenomics, Inc., a publicly traded company that operates a network of cancer-focused testing laboratories in the United States. It focuses on cancer genetic diagnostic, prognostic, and predictive testing services. The company primarily performs bone marrow aspirate and peripheral blood specimen sampling for the diagnosis of blood and lymphoid tumors; analysis of solid tumors, such as breast, lung, colon, and bladder cancer; and a Fluorescence In-Situ Hybridization (FISH) genetic test for the diagnosis of malignant melanoma.
In the company’s news yesterday,
NeoGenomics announced that it has developed and is now using new proprietary software for reading and interpreting Fluorescent in Situ Hybridization (“FISH”) digital data acquired manually or by an automated system.
The software is based on Support Vector Machine (SVM), which allows users to read and interpret specific types of FISH images more accurately and more quickly, and is a result of the company’s licensing agreement with Health Discovery Corp. It was through this agreement that NeoGenomics obtained exclusive worldwide rights to use SVM technology for all types of laboratory-developed tests in hematopoietic and solid tumor cancers.
NeoGenomics reports that it has confirmed and is currently implementing a laboratory-developed test using the new software to read ALK rearrangement FISH tests, which is a key component in selecting appropriate therapy for lung cancer patients. The company also intends to expand its use for other FISH probes.
“Development of this software is a result of our commitment to offer innovative solutions and uncompromising quality for cancer testing …,” Douglas VanOort, NeoGenomics chairman and CEO, stated in the press release. “We expect SVM technology will help us to automate certain manual testing processes, provide more accurate results for those tests that were previously dependent on subjective interpretations, and increase the productivity of our lab operations. To our knowledge, we are the first laboratory in the world to use SVM technology to assist in reading and interpreting ALK FISH data.”
Dr. Maher Albitar, NeoGenomics’ chief medical officer and director of research and development, noted the value that the system provides to lab technicians, in that they can train varying algorithms for specific types FISH images. Additionally, users have access to a library of files for reading and interpreting various FISH probes, which can be compiled for general use in any FISH laboratory that has a sublicense to the SVM technology.
“The science around using pattern recognition and computer-aided algorithms has improved significantly in the past few years. Our use of algorithms to interpret FISH digital data is just one step in a series of planned activities to adapt the SVM technology to cancer genetics testing. We believe these types of algorithms will be instrumental in helping to answer complex clinical questions and reducing the dependence on subjective interpretations,” Dr. Albitar stated.
NeoGenomics has applied for a utility patent on this methodology and the related software.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.